Lyell Immunopharma (LYEL) Enterprise Value (2020 - 2026)
Lyell Immunopharma (LYEL) posted Enterprise Value of -$254.0 million for Q1 2026, down 2.75% sequentially from -$247.2 million in Q4 2025, and up 15.66% YoY from -$219.6 million in Q1 2025.
Lyell Immunopharma (LYEL) Enterprise Value (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Enterprise Value for 7 years, with the latest figure at -$254.0 million in Q1 2026.
- Quarterly Enterprise Value rose 15.66% year-over-year to -$254.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$254.0 million (up 15.66% YoY) and the FY2025 annual result came in at -$247.2 million, up 33.28% from the prior year.
- Enterprise Value declined to -$254.0 million in Q1 2026 per LYEL's latest filing, from -$247.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$247.2 million in Q4 2025 and troughed at -$655.6 million in Q2 2022.
- A 5-year average of -$477.4 million and a median of -$526.3 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 151.22% in 2022, then soared 43.64% in 2025.
- Over 5 years, Enterprise Value stood at -$640.2 million in 2022, then gained by 14.67% to -$546.2 million in 2023, then soared by 32.17% to -$370.5 million in 2024, then surged by 33.28% to -$247.2 million in 2025, then slipped by 2.75% to -$254.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$254.0 million, -$247.2 million, and -$319.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -204.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -204.10 Mn |
| Mar 31, 2026 | -254.02 Mn |
| Dec 31, 2025 | -247.22 Mn |
| Sep 30, 2025 | -319.62 Mn |
| Jun 30, 2025 | -276.79 Mn |
| Mar 31, 2025 | -301.18 Mn |
| Dec 31, 2024 | -370.53 Mn |
| Sep 30, 2024 | -440.55 Mn |
| Jun 30, 2024 | -491.12 Mn |
| Mar 31, 2024 | -526.30 Mn |
| Dec 31, 2023 | -546.22 Mn |
| Sep 30, 2023 | -575.43 Mn |
| Jun 30, 2023 | -595.75 Mn |
| Mar 31, 2023 | -612.77 Mn |
| Dec 31, 2022 | -640.15 Mn |
| Sep 30, 2022 | -648.13 Mn |
| Jun 30, 2022 | -655.56 Mn |
| Mar 31, 2022 | -613.91 Mn |
| Dec 31, 2021 | -614.79 Mn |
| Sep 30, 2021 | -618.92 Mn |